CN-121985956-A - Composition and method for producing the same

Abstract

The present invention relates to cranberry fruit powder. In particular, the present invention relates to biological, therapeutic and non-therapeutic effects of cranberry fruit powder and compositions comprising the same.

Inventors

• E. A.C. Fuermantan
• M. Lekunte

Assignees

• 奇华顿股份有限公司
• 健合香港有限公司

Dates

Publication Date

20260505

Application Date

20241002

Priority Date

20231009

Claims (20)

1. 1. A cranberry fruit product for use in a method for reducing and/or inhibiting the growth of Gardnerella (Gardnerella) microorganisms in the urinary tract of a human or animal subject.
2. 2. A method of reducing gardnerella population in the urinary tract of a subject, the method comprising administering an effective amount of a cranberry fruit product to a human or animal subject.
3. 3. A cranberry fruit product for use in the prevention or treatment of Urinary Tract Infection (UTI) affecting a human or animal subject caused by the growth of a microorganism of the genus gardnerella.
4. 4. A cranberry fruit product for delaying the onset of Urinary Tract Infection (UTI) affecting a human or animal subject caused by the growth of a microorganism of the genus gardnerella.
5. 5. The cranberry fruit product for the use according to claim 4, wherein the delay in occurrence of UTIs is at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months or more between UTIs.
6. 6. The cranberry fruit product for the use according to claim 1, or the method according to claim 2, wherein the treatment results in the prevention of Urinary Tract Infection (UTI).
7. 7. The cranberry fruit product or method for the use according to any one of the preceding claims, wherein the use or method results in the prevention and/or treatment of recurrent UTI.
8. 8. The cranberry fruit product or method for the use according to any one of the preceding claims, wherein the treatment results in a reduction of UTI symptoms such as urgency and frequency.
9. 9. The cranberry fruit product or method for the use according to any one of the preceding claims, wherein the subject is experiencing UTI or is at risk of experiencing UTI.
10. 10. A non-therapeutic method of reducing gardnerella population in the urinary tract of a human or animal subject, the method comprising administering to the subject an effective amount of a cranberry fruit product.
11. 11. The non-therapeutic method of claim 10, wherein the subject is experiencing UTI or is at risk of experiencing UTI.
12. 12. The composition, method or non-therapeutic method for the use according to any one of the preceding claims, wherein the treatment results in the activation and/or inhibition of growth of escherichia coli (ESCHERICHIA COLI) in the bladder of the subject.
13. 13. The composition, method or non-therapeutic method for use according to any one of the preceding claims, wherein the cranberry fruit product is selected from one or more of cranberry juice, cranberry puree, cranberry pomace, dried cranberry powder, whole cranberry powder and/or cranberry extract.
14. 14. The composition, method or non-therapeutic method for use according to any one of the preceding claims, wherein the cranberry fruit product is enriched in cranberry seeds or cranberry seed powder.
15. 15. The composition, method or non-therapeutic method for use according to claim 14, wherein the seed or seed meal concentration is 5%, 10%, 15%, 20%, 25%, 30% or 35% or more by weight of the total cranberry fruit product.
16. 16. The composition, method or non-therapeutic method for use of claim 14, wherein the cranberry fruit product is a dry cranberry powder enriched in cranberry seeds or cranberry seed powder.
17. 17. The composition, method or non-therapeutic method for use according to claim 16, wherein the seed or seed powder concentration is 5%, 10%, 15%, 20%, 25%, 30% or 35% or more by weight of the dry cranberry powder, such as 5% to 35%, such as 15% to 25% by weight of the dry cranberry powder.
18. 18. The composition, method or non-therapeutic method for use according to claim 14, wherein the cranberry product is a dried cranberry powder obtained from cranberry juice and/or cranberry residue and/or cranberry puree and/or whole cranberry fruit, and is enriched in cranberry seeds or cranberry seed powder.
19. 19. The composition, method or non-therapeutic method for use according to claim 18, wherein the seed or seed powder concentration is 5%, 10%, 15%, 20%, 25%, 30% or 35% or more by weight of the cranberry powder, such as 5% to 35%, such as 15% to 25% by weight of the cranberry powder.
20. 20. The cranberry fruit product, method or non-therapeutic method for use according to any one of the preceding claims, wherein the cranberry fruit product comprises more than 0.3% (w/w) proanthocyanidin as determined according to BL-DMAC or more than 1.5% (w/w) proanthocyanidin as determined according to HPLC.

Description

Composition and method for producing the same Technical Field The present invention relates to cranberry fruit products. In particular, the present invention relates to biological, therapeutic and non-therapeutic effects of cranberry fruit products and compositions comprising the cranberry fruit products. Background Urinary Tract Infection (UTI) is among the most common infectious diseases and causes considerable health care expenditure to society. Microorganisms can reach the urinary tract through the blood or lymphatic pathways, but most clinical and experimental evidence suggests that the ascending urinary tract of microorganisms constitutes the most common pathway leading to urinary tract infections, particularly the ascending urinary tract of intestinal organisms (e.coli (ESCHERICHIA COLI) and other enterobacteria). Women are at a higher risk of suffering UTI than men. Dysbiosis is generally defined as, for example, an "imbalance" in the urine microbiota that is associated with a disease. The imbalance may be due to an increase or decrease in members of the community or a change in the relative abundance of microorganisms. Finding new ways to manage those UTIs and related dysbiosis is very valuable for patient comfort. Summary of The Invention The authors of the present invention have studied the biological effect of cranberry fruit products on Urinary Tract Infections (UTIs) and the effect of these products on human urinary tract microbiomes. The inventors of the present invention have unexpectedly observed that the relative abundance of Gardnerella (Gardnerella) in the female urine microbiome is significantly lower (p < 0.05) after 6 months of treatment with the cranberry fruit product of the present invention group compared to the placebo group. These findings are quite profound because the authors of the present disclosure have described an unexpected link between the effect of the cranberry product of the present invention, the abundance of gardnerella and the development of UTI and recurrent UTI. Gardnerella vaginalis (GARDNERELLA VAGINALIS) is a gram-stain-variable facultative anaerobic bacterial species. The organism is a small (1.0-1.5 μm diameter), sporulation-free, motionless, cocci. Has been classified as haemophilus vaginalis (Haemophilus vaginalis) and later as corynebacterium vaginalis (Corynebacterium vaginalis), gardnerella vaginalis (g. Vaginalis) is a facultative anaerobic gram-variable bacillus that, along with many other bacteria, primarily anaerobic, participates in bacterial vaginosis in some women due to disruption of the normal vaginal microbiota. Gardnerella is a common and often dominant member of the vaginal microbiome, especially in the case of dysbiosis (Morrill, sydney, nicole m. Gilbert, and Amanda L. Lewis. "Gardnerella vaginalis as a cause of bacterial vaginosis: appraisal of the evidence from in vivo models." Frontiers in cellular and infection microbiology 10 (2020): 168). Urine is the second most common source of gardnerella isolated following the vagina. As previously stated, the inventors of the present invention have unexpectedly observed that the relative abundance of gardnerella in the female urine microbiome is significantly lower (p < 0.05) after 6 months of treatment with the cranberry fruit product of the present invention group compared to the placebo group. Thus, in a first aspect, the present invention relates to a cranberry fruit product according to the present invention for use in a method of reducing and/or inhibiting the growth of gardnerella microorganisms in the urinary tract of a human or animal subject. In a second aspect, the invention relates to a method of reducing gardnerella population in the urinary tract of a subject, the method comprising administering to a human or animal subject an effective amount of a cranberry fruit product according to the invention. In fact, it is described that women with bacterial vaginosis caused by overgrowth of anaerobic species such as some strains belonging to gardnerella vaginalis are more prone to UTI (Sumati, a.h.), and than women with a healthy microflora consisting mainly of Lactobacillus (Lactobacillus), and N. K. Saritha. "Association of urinary tract infection in women with bacterial vaginosis." Journal of global infectious diseases 1.2 (2009): 151.). Thus, in a third aspect, the present invention relates to a cranberry fruit product according to the present invention for use in the prevention or treatment of Urinary Tract Infection (UTI) affecting a human or animal subject caused by the growth of microorganisms of the genus gardnerella. In a fourth aspect, the present invention relates to a cranberry fruit product according to the present invention for use in delaying the onset of Urinary Tract Infection (UTI) affecting a human or animal subject caused by the growth of microorganisms of the genus gardnerella. In a further aspect, the invention relates to a non-therapeutic method of reducing gardner